Amphastar Pharmaceuticals, Inc. has exceeded street estimates of its performance for the third consecutive quarter as it delivered better-than-expected Q2 revenue, driven by sales of glucagon and phytonadione.
Amphastar Beats The Street For Third Consecutive Quarter
Firm Stands To Gain Further In H2 Following Pfizer Tornado Damage
Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.
More from Earnings
More from Business
• By
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
• By
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.
• By
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.